Oncology and Hematology

Jean Grem, M.D.

Dr. GremProfessor, Internal Medicine
Division of Hematology & Oncology

Academic office:
UNMC Oncology/Hematology Division
987680 Nebraska Medical Center
Omaha, NE 681980-7680

Main practice location:
Peggy D. Cowdery Patient Care Center
Lied Transplant Center
987835 Nebraska Medical Center
Omaha, NE 68198-7835

Cancer Center at Village Pointe
111 North 175th Street
Omaha, NE 68118
Ph. 402-596-3100

Education:
1972-1976 Purdue University, Biology
1976-1980 Jefferson Medical College, Medicine
1980-1983 University of Iowa Hospitals & Clinics, Internal Medicine
1983-1986 University of Wisconsin Clinical Cancer Center, Medical Oncology

Hospital Appointments:
The Nebraska Medical Center University Hospital

Interests:
Colorectal and other Gastrointestinal Cancers and Neuroendocrine (Carcinoid Tumors)

Biographical Sketch:
Dr. Grem is Professor of Medicine and joined UNMC in 2003. Prior to joining UNMC, Dr. Grem was Senior Investigator at the National Cancer Institute, in Bethesda, Maryland since 1986. She became the Head of the Gastrointestinal Malignancies Division, Cancer Therapeutics Branch at the National Cancer Institute in 2001. Dr. Grem is known nationally as an expert in gastrointestinal malignancies and is currently exploring several novel therapeutic approaches in both colon and pancreatic cancer at UNMC. Dr. Grem is currently the Associate Director for Translational Research of the UNMC Eppley Cancer Center. Dr. Grem has published over 110 peer-reviewed articles in various cancer-related medical journals. Dr. Grem reviews for various oncology and basic science journals and has been invited to review grant application in various funding agencies.

Select Publications:
Grem JL, Harold N, Shapiro J, et al. A phase I and pharmacokinetic trial of weekly oral 5-flurouracil given with eniluracil and low-dose leucovorin. J Clin Oncol 18:3952-3963, 2000.

Grem JL, Yee LK, Schuler B, et al. Phosphonacetyl-L-aspartate and calcium leucovorin modulation of fluorouracil administered by constant rate and circadian pattern of infusion over 72-hours in metastatic gastrointestinal adenocarcinoma. Ann Oncol 12:1581-1587, 2001.

Grem JL, Harold N, Keith B, et al. A phase I pharmacologic and pharmacodynamic study of pyrazoloacridine given as a weekly 24-hour continuous intravenous infusion in adult cancer patients. Clin Cancer Res. 8:2149-2156, 2002.

Grem JL, Quinn MG, Keith B, et al. Phase I trial of weekly gemcitabine in combination with infusional 5-fluorodeoxyuridine and oral calcium leucovorin in adult cancer patients. Cancer Chemother Pharmacol 53:487-496, 2003.

Grem JL, Morrison G, Guo XD, et al. A phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adults with solid tumors. J Clin Oncol. 23:1885-93, 2005.

;